Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.
about
Oncolytic viruses as therapeutic cancer vaccinesBig Data Offers Novel Insights for Oncolytic Virus ImmunotherapyThe profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsDefining Effective Combinations of Immune Checkpoint Blockade and Oncolytic VirotherapyMurine Tumor Models for Oncolytic Rhabdo-Virotherapy.Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytesDefinitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral ImmunotherapyDetecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.Evolution of oncolytic viruses: novel strategies for cancer treatment.The use of endogenous T cells for adoptive transfer.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Oncolytic virus immunotherapy for melanoma.Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.Oncolytic Virotherapy: A Contest between Apples and Oranges.Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.Improving the outcome of adoptive cell transfer by targeting tumor escape.Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting.Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.Oncolytic Adenoviruses in Cancer Treatment.Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.
P2860
Q21245758-9A94A6E8-D34B-4A44-AD9E-E45347540CE5Q26767209-E88D083B-544F-48B5-98F8-C6A75BF800D1Q35212733-AB6802B3-7D16-48FD-A1B3-764AC01C3126Q35534823-6C13BB92-D001-4401-AC48-41871370E84FQ36378248-CED143D2-5DD0-49B7-A880-05C7708EE6ECQ36751597-DD666166-E8D1-4864-86BA-48F1174FC1B7Q36911654-DFC650F0-F468-4A72-8B7F-28342F17576BQ36928875-645CD13B-EFCC-468E-9619-94A76D63464FQ37477557-3E7FDC23-F61C-4A23-B581-D35F0413A88EQ38159802-7C729A7A-A3BC-4AB6-997F-B935BC6762DEQ38170503-1928573D-619F-4214-B48D-241316A064DAQ38223419-067C18C0-8C78-4252-A7F5-85E995093DC3Q38357137-0E8F2E5A-2F5B-4F43-BD87-2F6A09B31A62Q38380394-EE90945F-6926-4523-83F9-3FDEA06CCEDFQ38924539-3CB071A5-DD28-4F01-B76C-094A4D1530BFQ38941936-5A8ADE21-CA98-4C24-909C-6D3F87AF277CQ39230055-8EFFAFD9-13D5-4BCF-9CDD-A01157705462Q39387174-3A1ED15F-1DDA-4CB4-9BAB-6735EFD83177Q40104793-5D4560CF-232C-4D32-8AF9-FF24C27B417FQ41914105-5A7DAE55-1E2D-457C-8757-4123A6946277Q45323818-FDB9CB6D-8A27-48A5-AA6F-462E02458D37Q45324769-E5CBEE99-4F83-41F5-BFAD-EBA61EA52221Q45865962-0D3379F5-4E2E-43D9-AD77-19DF2A1D3354Q46507832-BFD45226-1935-4F18-ACB2-7E2F4A0D9AD4Q47781149-1635CBA4-E0AD-4ED6-858F-59AA05CBCFFAQ51849210-0C565E20-64F3-445C-811D-A577F0E09FE5Q54221621-DE50EBA8-648C-4390-B1D2-DB052BDE7BE5Q54378300-B75AA4E1-DA81-4ECA-A4CF-52E46134F3B5Q55085319-6D0D56DB-C51B-4FDC-99EA-F729744AD7A3Q55652233-4EDF34E8-468E-4255-8868-58B6BBEA2917
P2860
Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Systemic combination virothera ...... and adoptive T-cell transfer.
@en
type
label
Systemic combination virothera ...... and adoptive T-cell transfer.
@en
prefLabel
Systemic combination virothera ...... and adoptive T-cell transfer.
@en
P2093
P2860
P1433
P1476
Systemic combination virothera ...... and adoptive T-cell transfer.
@en
P2093
Diana M Rommelfanger
Jill M Thompson
Karen M Kaluza
Phonphimon Wongthida
Richard G Vile
Rosa M Diaz
Timothy J Kottke
P2860
P304
P356
10.1158/0008-5472.CAN-12-0600
P407
P577
2012-07-26T00:00:00Z